Comparison between pre-treatment with nalbuphine vis-a-vis dexmedetomidine for prevention of etomidate induced myoclonus

Authors

  • Manoj Kumar Saha Senior Resident, Department of Anaesthesiology, Calcutta National Medical College and Hospital, Kolkata, West Bengal, India
  • Parvin Banu Associate Professor, Department of Anaesthesiology, Calcutta National Medical College and Hospital, Kolkata, West Bengal, India
  • Sayantan Mukhopadhyay Assistant Professor, Department of Anaesthesiology, Calcutta National Medical College and Hospital, Kolkata, West Bengal, India
  • Arunava Biswas Associate Professor, Department of Pharmacology, Maharaja Jitendra Narayan Medical College and Hospital, Coochbehar, West Bengal, India https://orcid.org/0000-0002-9676-3410
  • Susmita Bhattacharyya Professor, Department of Anaesthesiology, Calcutta National Medical College and Hospital, Kolkata, West Bengal, India

DOI:

https://doi.org/10.3126/ajms.v14i3.50106

Keywords:

Anesthesia; Etomidate; Nalbuphine; Myoclonus

Abstract

Background: Etomidate is considered as an excellent drug for induction in anesthesia, although it has an undesirable side effect like myoclonus.

Aims and Objectives: The aims of this study were to compare the effect between pre-treatment with nalbuphine and dexmedetomidine for attenuation and severity of etomidate induced myoclonus and to assess their adverse drug reaction.

Materials and Methods: A prospective, randomized, and single-blinded study was conducted on patients undergoing elective surgery under general anesthesia. After selection of patients according to inclusion/exclusion criteria, nalbuphine (0.2 mg/kg) and dexmedetomidine (0.5 μg/kg) were infused 10 min before the induction of anesthesia. The vital parameters and any incidences of myoclonus during operation were observed at fixed interval.

Results: A total of 102 patients in the age group of 18–60 years of either sex were assessed. In Group D 7, out of 51 patients (13.7%) were found to have myoclonus, whereas, in Group N, it was observed in 21 out of 51 patients (41.2%). Difference between the two was found to be statistically significant (P<0.001). In Group D, grade 3 myoclonus was observed in 0% patients. About 2% patients had grade 2 and 11.8% had grade 3 myoclonus. In Group N, grade 3, 2, and 1 myoclonus was recorded as 3.9%, 11.8%, and 25.5%, respectively. The difference between the two groups is statistically significant (P<0.001).

Conclusion: Incidence and severity of etomidate induced myoclonus were less in patients who received pre-treatment with dexmedetomidine than those who underwent pre-treatment with nalbuphine. Furthermore, more hemodynamic stability was achieved with use of dexmedetomidine as the agent for pre-treatment.

Downloads

Download data is not yet available.
Abstract
35
PDF
58

Downloads

Published

2023-03-01

How to Cite

Saha, M. K. ., Banu, P. ., Mukhopadhyay, S. ., Biswas, A., & Bhattacharyya, S. . (2023). Comparison between pre-treatment with nalbuphine vis-a-vis dexmedetomidine for prevention of etomidate induced myoclonus. Asian Journal of Medical Sciences, 14(3), 28–32. https://doi.org/10.3126/ajms.v14i3.50106

Issue

Vol. 14 No. 3 (2023)

Section

Original Articles

License

Copyright (c) 2022 Asian Journal of Medical Sciences

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Authors who publish with this journal agree to the following terms:

  1. The journal holds copyright and publishes the work under a Creative Commons CC-BY-NC license that permits use, distribution and reprduction in any medium, provided the original work is properly cited and is not used for commercial purposes. The journal should be recognised as the original publisher of this work.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).